Genome-wide analysis of epigenetic silencing identifies BEX1 and BEX2 as candidate tumor suppressor genes in malignant glioma.

Promoter hypermethylation and histone deacetylation are common epigenetic mechanisms implicated in the transcriptional silencing of tumor suppressor genes in human cancer. We treated two immortalized glioma cell lines, T98 and U87, and 10 patient-derived primary glioma cell lines with trichostatin A (TSA), a histone deacetylase inhibitor, or 5-aza-2'-deoxycytidine (5-AzaC), a DNA methyltransferase inhibitor, to comprehensively identify the cohort of genes reactivated through the pharmacologic reversal of these distinct but related epigenetic processes. Whole-genome microarray analysis identified genes induced by TSA (653) or 5-AzaC treatment (170). We selected a subset of reactivated genes that were markedly induced (greater than two-fold) after treatment with either TSA or 5-AzaC in a majority of glioma cell lines but not in cultured normal astrocytes. We then characterized the degree of promoter methylation and transcriptional silencing of selected genes in histologically confirmed human tumor and nontumor brain specimens. We identified two novel brain expressed genes, BEX1 and BEX2, which were silenced in all tumor specimens and exhibited extensive promoter hypermethylation. Viral-mediated reexpression of either BEX1 or BEX2 led to increased sensitivity to chemotherapy-induced apoptosis and potent tumor suppressor effects in vitro and in a xenograft mouse model. Using an integrated approach, we have established a novel platform for the genome-wide screening of epigenetically silenced genes in malignant glioma. This experimental paradigm provides a powerful new method for the identification of epigenetically silenced genes with potential function as tumor suppressors, biomarkers for disease diagnosis and detection, and therapeutically reversible modulators of critical regulatory pathways important in glioma pathogenesis.

[1]  Christoph Plass,et al.  Cancer epigenomics. , 2002, Human molecular genetics.

[2]  D. Sidransky,et al.  Quantitation of GSTP1 methylation in non-neoplastic prostatic tissue and organ-confined prostate adenocarcinoma. , 2001, Journal of the National Cancer Institute.

[3]  N. Ikegaki,et al.  Antitumor activity of CEP-751 (KT-6587) on human neuroblastoma and medulloblastoma xenografts. , 1999, Clinical cancer research : an official journal of the American Association for Cancer Research.

[4]  Matty P. Weijenberg,et al.  A genomic screen for genes upregulated by demethylation and histone deacetylase inhibition in human colorectal cancer , 2002, Nature Genetics.

[5]  R. Mirimanoff,et al.  MGMT gene silencing and benefit from temozolomide in glioblastoma. , 2005, The New England journal of medicine.

[6]  Xu Zhou.  Trichostatin A inhibits proliferation of human tumor cell and induces expression of p21 , 2007 .

[7]  司履生.  Cancer epigenetics , 2006 .

[8]  G. Reifenberger,et al.  Hypermethylation and transcriptional downregulation of the carboxyl-terminal modulator protein gene in glioblastomas. , 2004, Journal of the National Cancer Institute.

[9]  M. Ciesielski,et al.  Synergistic Cytotoxicity, Apoptosis and Protein-linked DNA Breakage by Etoposide and Camptothecin in Human U87 Glioma Cells: Dependence on Tyrosine Phosphorylation , 1999, Journal of Neuro-Oncology.

[10]  J. Herman,et al.  A systematic profile of DNA methylation in human cancer cell lines. , 2003, Cancer research.

[11]  T. Mima,et al.  Histone deacetylase inhibitors such as sodium butyrate and trichostatin A inhibit vascular endothelial growth factor (VEGF) secretion from human glioblastoma cells , 2006, Brain Tumor Pathology.

[12]  J. Herman,et al.  Synergy of demethylation and histone deacetylase inhibition in the re-expression of genes silenced in cancer , 1999, Nature Genetics.

[13]  P. Green,et al.  Consed: a graphical tool for sequence finishing. , 1998, Genome research.

[14]  Robert Brown,et al.  Epigenomics and epigenetic therapy of cancer. , 2002, Trends in molecular medicine.

[15]  Jae-Geun Yoon,et al.  Role of Mitogen-Activated Protein Kinases in CpG DNA-Mediated IL-10 and IL-12 Production: Central Role of Extracellular Signal-Regulated Kinase in the Negative Feedback Loop of the CpG DNA-Mediated Th1 Response1 , 2002, The Journal of Immunology.

[16]  C. Desmarais,et al.  Automated finishing with autofinish. , 2001, Genome research.

[17]  P. Green,et al.  Base-calling of automated sequencer traces using phred. I. Accuracy assessment. , 1998, Genome research.

[18]  O. Yokosuka,et al.  Identification of genes up-regulated by histone deacetylase inhibition with cDNA microarray and exploration of epigenetic alterations on hepatoma cells. , 2004, Journal of hepatology.

[19]  J. Herman,et al.  Molecular detection of prostate cancer in urine by GSTP1 hypermethylation. , 2001, Clinical cancer research : an official journal of the American Association for Cancer Research.

[20]  R. Kandolf,et al.  Inhibitors of DNA methylation and histone deacetylation activate cytomegalovirus promoter-controlled reporter gene expression in human glioblastoma cell line U87. , 2003, Carcinogenesis.

[21]  Rudolf Fahlbusch,et al.  Suberoylanilide hydroxamic acid (SAHA) has potent anti‐glioma properties in vitro, ex vivo and in vivo , 2005, Journal of neurochemistry.

[22]  Rui Henrique,et al.  Quantitative GSTP1 hypermethylation in bodily fluids of patients with prostate cancer. , 2002, Urology.

[23]  K. Srivenugopal,et al.  Promoter methylation and silencing of the tissue factor pathway inhibitor-2 (TFPI-2), a gene encoding an inhibitor of matrix metalloproteinases in human glioma cells. , 2003, Oncogene.

[24]  L. Greene,et al.  NADE, a p75NTR-associated Cell Death Executor, Is Involved in Signal Transduction Mediated by the Common Neurotrophin Receptor p75NTR* , 2000, The Journal of Biological Chemistry.

[25]  Kelly M. McGarvey,et al.  Silenced tumor suppressor genes reactivated by DNA demethylation do not return to a fully euchromatic chromatin state. , 2006, Cancer research.

[26]  J. Cameron,et al.  Discovery of novel targets for aberrant methylation in pancreatic carcinoma using high-throughput microarrays. , 2003, Cancer research.

[27]  K. Schuebel,et al.  Differential requirement for DNA methyltransferase 1 in maintaining human cancer cell gene promoter hypermethylation. , 2006, Cancer research.

[28]  P. Laird.  Cancer epigenetics. , 2005, Human molecular genetics.

[29]  K. Srivenugopal,et al.  Promoter methylation and silencing of the tissue factor pathway inhibitor-2 (TFPI-2), in human glioma cells , 2003, Oncogene.

[30]  H. Yoshioka,et al.  Epigenetic silencing of PEG3 gene expression in human glioma cell lines * , 2001, Molecular carcinogenesis.

[31]  Y. Roussos,et al.  O6-methyl-guanine-DNA methyltransferase methylation in serum and tumor DNA predicts response to 1,3-bis(2-chloroethyl)-1-nitrosourea but not to temozolamide plus cisplatin in glioblastoma multiforme. , 2003, Clinical cancer research : an official journal of the American Association for Cancer Research.

[32]  F. Sato,et al.  Pharmacologic unmasking of epigenetically silenced tumor suppressor genes in esophageal squamous cell carcinoma. , 2002, Cancer cell.

[33]  E. Ballestar,et al.  The epigenetic breakdown of cancer cells: from DNA methylation to histone modifications. , 2005, Progress in molecular and subcellular biology.

[34]  John D. Storey,et al.  Statistical significance for genomewide studies , 2003, Proceedings of the National Academy of Sciences of the United States of America.

[35]  M. Esteller.  Dormant hypermethylated tumour suppressor genes: questions and answers , 2005, The Journal of pathology.

[36]  Peter A. Jones,et al.  Overview of cancer epigenetics. , 2005, Seminars in hematology.

[37]  Peter A. Jones,et al.  Discovery of Epigenetically Masked Tumor Suppressor Genes in Endometrial Cancer , 2005, Molecular Cancer Research.

[38]  Scar,et al.  Inactivation of the DNA-repair gene MGMT and the clinical response of gliomas to alkylating agents. , 2000, The New England journal of medicine.

[39]  P. Massi,et al.  Antitumor Effects of Cannabidiol, a Nonpsychoactive Cannabinoid, on Human Glioma Cell Lines , 2004, Journal of Pharmacology and Experimental Therapeutics.

[40]  P Green,et al.  Base-calling of automated sequencer traces using phred. II. Error probabilities. , 1998, Genome research.

[41]  A. Feinberg,et al.  The history of cancer epigenetics , 2004, Nature Reviews Cancer.

[42]  B. Dörken,et al.  Induction of gene expression by 5-Aza-2′-deoxycytidine in acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS) but not epithelial cells by DNA-methylation-dependent and -independent mechanisms , 2005, Leukemia.

[43]  C. Lopes,et al.  Detection of gene promoter hypermethylation in fine needle washings from breast lesions. , 2003, Clinical cancer research : an official journal of the American Association for Cancer Research.

[44]  M. Paz,et al.  CpG Island Hypermethylation of the DNA Repair Enzyme Methyltransferase Predicts Response to Temozolomide in Primary Gliomas , 2004, Clinical Cancer Research.

[45]  Richard LeBlanc,et al.  Suppression of Rac activity induces apoptosis of human glioma cells but not normal human astrocytes. , 2002, Cancer research.

[46]  D. Sidransky,et al.  Quantitative adenomatous polyposis coli promoter methylation analysis in tumor tissue, serum, and plasma DNA of patients with lung cancer. , 2002, Cancer research.